Intellipharmaceutics seeks to market generic Seroquel XR

TORONTO — Canadian drug maker Intellipharmaceutics International is seeking approval for a generic version of a treatment for mental disorders.

Intellipharmaceutics announced Monday that it had filed an application with the Food and Drug Administration for quetiapine fumarate extended-release tablets, a generic version of AstraZeneca’s Seroquel XR.

Seroquel XR is used to treat schizophrenia, bipolar disorder and major depressive disorder. It had sales of about $823 million in 2010, according to Intellipharmaceutics. The last of the patents covering Seroquel XR expire in 2017, according to FDA records.